TOP TEN perturbations for 11759711_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 11759711_a_at
Selected probe(set): 212027_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 11759711_a_at (212027_at) across 5779 perturbations tested by GENEVESTIGATOR:

adrenal gland cancer study 4 / normal adrenal cortex tissue

Relative Expression (log2-ratio):3.8748531
Number of Samples:43 / 4
Experimental adrenal gland cancer study 4
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC).
Control normal adrenal cortex tissue
Histological normal adrenal gland cortical tissue samples derived after autopsy.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):3.5959806
Number of Samples:16 / 33
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):3.5587444
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):3.484314
Number of Samples:28 / 14
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they were alive.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they were alive.

DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):3.4594707
Number of Samples:91 / 43
Experimental DLBCL study 4 (GCB DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive.
Control DLBCL study 4 (GCB DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with germinal-center B-cell–like subtype of diffuse large B-cell lymphoma (GCB DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive.

DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):3.4118671
Number of Samples:54 / 19
Experimental DLBCL study 4 (ABC DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they were alive.
Control DLBCL study 4 (ABC DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they were alive.

DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead) / DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)

Relative Expression (log2-ratio):-3.2647123
Number of Samples:55 / 39
Experimental DLBCL study 4 (ABC DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). During follow up period they died from unknown reasons.
Control DLBCL study 4 (ABC DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with activated B-cell–like subtype of diffuse large B-cell lymphoma (ABC DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP). During follow up period they died from unknown reasons.

ovarian tumor study 11 (high grade) / ovarian tumor study 11 (low grade)

Relative Expression (log2-ratio):-3.1741695
Number of Samples:22 / 11
Experimental ovarian tumor study 11 (high grade)
Human microdissected tumor cells from the ovary of patients with high grade serous carcinoma.
Control ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.

kidney transplantation study 16 (2 week) / normal natural killer cell (CD56+) sample

Relative Expression (log2-ratio):-3.0869637
Number of Samples:3 / 3
Experimental kidney transplantation study 16 (2 week)
CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal natural killer cell (CD56+) sample
CD56+ natural killer cell samples derived from healthy control subjects.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):3.0449572
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.